Abstract
Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains. BACKGROUND: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. MATERIALS AND METHODS: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. RESULTS: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. CONCLUSIONS: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.